India Globalization Capital THC Based Alzheimer’s Treatment and Full Pipeline Review

NEW YORK, NY / ACCESSWIRE / July 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on India Globalization Capital Inc. (NYSE MKT: IGC) develops intellectual property for the treatment of life-altering or life-threatening conditions, through its research on phytocannabinoid therapies, in the United States. Presently IGC is focusing more on development of cannabis-based therapies to treat cachexia, nausea, vomiting, Parkinson’s disease, Alzheimer’s disease, epilepsy, PTSD, and other life-altering conditions

In 2017 Medicare and Medicaid alone are expected to spend $175 billion on patients diagnosed with Alzheimer’s. There are currently over 5.3 million Americans with Alzheimer’s (AD). The cost of Alzheimer’s has increased significantly and is expected to continue to surge higher. The number of patients is expected to double over the next 20 years and the direct costs are expected to exceed $450 billion per year in the next 12 years. There is still no accepted cure for Alzheimer’s disease.

During June 2017, IGC announced that it has entered into a definitive license agreement with the University of South Florida making it an exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” By acquiring this patent filing, IGC is protecting a potential cannabis-based blockbuster treatment for America’s most expensive disease.

Review the complete IGC product pipeline and get a financial review in this report READ MORE.

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/igc/

In the past few years, research around cannabis has grown. Clinical trials have begun to reflect that side effects of THC and other cannabis products are tolerable to patients and reduce with time. There is trial data highlighting that, at proper doses, cannabinoids have positive side effects for Alzheimer’s patients, such as a reduction in delusions and mood disorders.

The research on the effect of THC on Alzheimer’s patients’ cognitive function is also validated in two papers. One, published by the Salk Institute in 2016, validated the University of South Florida’s finding that low doses of THC break up amyloid-beta plaques on neurons. Another, published this year in Nature, confirmed the therapeutic promise, showing that cognitive function was restored in aged mice, which were provided low doses of THC. The company is aggressively focusing on assembling a strong development team and a primary pipeline of four major products addressing large markets and possible blockbuster indications utilizing cannabis-based therapies.

Read how cannabis impacts Alzheimer’s and get a 2017 IGC outlook READ MORE.

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/igc/

DISCLOSURE

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 467670